There was a sizeable drop in the number of open positions needing a filling at A.C.A.C. Immune S.A.S.A. during December. The total number of shares subject to short interest was 243,200 as of December 30. This represents a decrease of 24.4% from the total number of 321,700 shares subject to short interest as of December 15. Right now, short sales account for 0.6% of the total shares outstanding in the company. The days-to-cover ratio is currently at 1.6 days, which can be attributed to the average trading volume of 148,500 shares.
On Friday, October 28, the most recent earnings report for A.C.A.C. Immune (NASDAQ: A.C.I.U.) was made available to the general public. The company reported earnings per share (EPS) for the period at $0.17, which was $0.07 higher than the consensus expectation of $0.24. The company reported revenue for the quarter of $4.07 million, which was significantly higher than the average projection of $0.73 million, which analysts made. According to projections made by industry experts, A.C.A.C. Immune is expected to report a loss of -0.9 cents on each share in 2018.
When the market opened on Thursday, the price of an A.C.A.C. Immune share was $2.33 per unit. The price of A.C.A.C. Immune during the previous year ranged from a low of $1.68 to a high of $4.93 at various points. The current market cap for the company is $194.68 million, the price-to-earnings ratio for the stock is -2.48, and the beta value is 0.57. The average price of the company’s stock over the past 50 days is calculated to be $2.29, and its average price over the past 200 days is $2.80.
Over the past few months, a few hedge funds have actively bought and sold shares. A new investment totaling approximately 1,208,000 dollars was made in A.C.A.C. Immune by Assenagon Asset Management S.A.S.A. during the final three months of 2018. Additional investments were made during the third quarter by Balyasny Asset Management L.L.C. These new investments brought the total value of the company’s stake in A.C.A.C. Immune to approximately $82,000. Kingsbury Capital Investment Advisors L.L.C. successfully acquired an additional 44.6% of the total number of A.C.A.C. Immune common stock available during the third quarter. During the most recent quarter, Kingsbury Capital Investment Advisors L.L.C. increased its holdings in the company by purchasing an additional 8,423 shares. This resulted in an increase of $86,000 in its active holdings in the buying and selling shares. A new investment totaling approximately 1,208,000 dollars was made in A.C.A.C. Immune by Assenagon Asset Management S.A.S.A. during the final three months of 2018. Additional investments were made during the third quarter by Balyasny Asset Management L.L.C. These new investments brought the total value of the company’s stake in A.C.A.C. Immune to approximately $82,000. Kingsbury Capital Investment Advisors L.L.C. successfully acquired an additional 44.6% of the total number of A.C.A.C. Immune common stock available during the third quarter. During the most recent quarter, Kingsbury Capital Investment Advisors L.L.C. increased its holdings in the company by purchasing an additional 8,423 shares. This increased to $86,000 in its holdings. As a result, the total number of shares acquired by the company is 27,291. During the second quarter, Renaissance Technologies L.L.C. completed a 4.9% increase in the proportion of A.C.A.C. Immune owned by the company. After making an additional purchase of 22,100 shares during the preceding quarter, Renaissance Technologies L.L.C. now owns 474,590 shares. Based on the current share price, this gives the company a total market value of $1,713,000. And finally, during the second quarter, UBS Group AG saw a 191.2% increase in the value of its ownership interests in A.C.A.C. Immune, bringing the total value of those interests to
